A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Phase 2
130
about 4.1 years
18+
15 sites in CT, FL, GA +8
What this study is about
Researchers are testing whether adding a treatment to chemotherapy and radiation therapy, followed by immunotherapy, can improve the response rate in people with advanced lung cancer. The trial will last about 1486 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Concurrent Chemo/Radiation Therapy (cCRT)
- 2.Receive Durvalumab
- 3.Take Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin
- +2 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
chemotherapy, durvalumab
infusion
Primary: Objective Response Rate (ORR) Using Independent Central Review (ICR) Assessment
Secondary: Disease Control Rate (DCR) Post-cCRT and Pre-cIT, Duration of Response (DoR), Number of Participants Reporting Laboratory Parameters, Physical Examination, Vital Signs Including Eastern Cooperative Oncology Group (ECOG) Performance Status Abnormalities, Number of Participants with Treatment-Emergent Adverse Event (TEAE) Related to Study Treatment, Objective Response Rate (ORR) Post-cCRT and Pre-cIT, Objective Response Rate (ORR) as Assessed by the Investigator, Progression Free Survival (PFS)
radiation
Oncology